ABSTRACT
Rituximab is efficacious in myelin-associated glycoprotein (MAG) polyneuropathy, but the question on timing of retreatments is open. We studied 21 anti-MAG polyneuropathy patients who responded to a first cycle of rituximab, were followed-up for an average of 11.2â¯years, and were retreated only when relapsing. Baseline serum B-cell-activating factor (BAFF) levels were measured. Clinical improvements lasted on average 6â¯years, and as many as 71% of the patients resulted long-lasting responders. Severity of disease and high serum BAFF levels (cut-off ≥860â¯pg/mL for relapse risk) at onset seemed to predict worse prognosis. Measurements of these variables could help deal with the issue of maintenance rituximab therapy in MAG polyneuropathy.
Subject(s)
Autoantibodies/blood , Immunologic Factors/administration & dosage , Myelin-Associated Glycoprotein/blood , Polyneuropathies/blood , Polyneuropathies/drug therapy , Rituximab/administration & dosage , Adult , Aged , Aged, 80 and over , Autoantibodies/immunology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myelin-Associated Glycoprotein/immunology , Polyneuropathies/immunology , Time Factors , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Drug Hypersensitivity/diagnosis , Imatinib Mesylate/adverse effects , Desensitization, Immunologic/methods , Skin Tests , Leukemia, Myeloid/drug therapy , Antineoplastic Agents/adverse effects , Hypersensitivity, Immediate/therapyABSTRACT
Flushing totally implantable venous access devices (TIVADs) with manually filled saline syringes may increase contamination and catheter-related bloodstream infection (CRBSI). We used a retrospective cohort study to assess the impact of changing from manually filled syringes to manufactured pre-filled syringes on the frequency of CRBSI in 718 TIVADs. Manually filled syringes were used in 269 patients and pre-filled syringes in 449. The CRBSI rate was 2.7% in the pre-filled syringe group and 6.3% in the manually filled syringe group (P = 0.016). Sex, tumour type and stage, access site and access body side were not independent risk factors for CRBSI.
Subject(s)
Catheter-Related Infections/prevention & control , Equipment Contamination/prevention & control , Syringes , Adult , Catheter-Related Infections/microbiology , Catheterization, Central Venous/adverse effects , Female , Humans , Incidence , Logistic Models , Male , Multivariate Analysis , Neoplasms/microbiology , Neoplasms/therapy , Pilot Projects , Retrospective Studies , Risk Factors , Sodium ChlorideABSTRACT
OKT3 is a monoclonal antibody used as T-specific immunosuppressor agent in the treatment of acute rejection of hepato- or renal-transplanted patients. The immunosuppressor effect is related to the elimination and modulation of T-cells after the binding between OKT3 and the specific antigen CD3+. This drug has been used in the treatment of acute rejection. The more frequent side effects is the immunogenic reaction Human Antibody Mouse Antibody (HAMA). The aim of this study is the evaluation of the dose and the administration route of the OKT3. The results of the antibody monitoring in the plasma of the treated patients and the analysis of the clinical data were evaluated to focus a valid therapeutic protocol as well as a more rational time sampling of the circulating drug to achieve a correct monitoring. The results show a gradual increase of the hematic concentration of the drug, positively correlating the clinical data of hepatic biopsy and lymphocytic screening. These results have permitted to modify the therapeutic protocol previously performed. It has been defined the administration route choosing i.v. infusion (5 mg/die/2 h), moreover it the therapy has been shortened to 6 days. The HAMA were also evaluated and the analysis of the data showed a negative results, suggesting the possibility of the OKT3 retreatment in the cases of rescue.
